MAPT and Alzheimer disease: The characterization of the preclinical stage of AD first became possible following neuroimaging with magnetic resonance imaging (MRI) and positron emission tomography (PET), reflecting cerebral amyloidosis, tau phosphorylation and neurodegeneration.